QuantumPharm, Inc. (2228) AI Stock Analysis

• Market Cap: HK$48.17B
• Dividend Yield: N/A
• Average Volume (3M): 143.30M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.90
• Revenue Growth: 243.78%
• EPS Growth: 97.15%
• Country: HK
• Employees: 809
• Sector: General
• Sector Strength: N/A
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.02
• Shares Outstanding: 4,302,922,000
• 10 Day Avg. Volume: 160,836,692
• 30 Day Avg. Volume: 143,301,077
• PEG Ratio: 0.00
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 40.47
• P/FCF Ratio: -20.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: HK$12.00 ▲(3.72% Upside)

QuantumPharm, Inc.'s stock score is primarily influenced by its strong technical performance, indicating positive market momentum. However, financial performance concerns, including persistent losses and negative cash flows, weigh heavily on the overall score. Valuation challenges further impact the stock's attractiveness.

Positive Factors

Revenue Growth

The company's robust revenue growth indicates a successful expansion of its market presence and product adoption, which is crucial for long-term sustainability and competitiveness in the biotech industry.

Balance Sheet Improvements

Improved debt levels and a positive equity position enhance financial stability, providing a stronger foundation for future growth and reducing financial risk.

Gross Profit Margin Improvement

An improved gross profit margin suggests better cost management and pricing power, which can lead to enhanced profitability over time as the company scales.

Negative Factors

Profitability Challenges

Ongoing net losses and negative profit margins highlight significant challenges in achieving profitability, which could hinder long-term financial health and investor confidence.

Negative Cash Flows

Persistent negative cash flows limit the company's ability to fund operations and growth internally, potentially leading to increased reliance on external financing.

Operational Efficiency Concerns

Inefficient operations, as indicated by negative EBIT and EBITDA margins, suggest the need for strategic improvements to enhance cost control and operational effectiveness.

QuantumPharm, Inc. Business Overview & Revenue Model

Company Description

QuantumPharm, Inc. (2228) is a biotechnology company focused on developing innovative therapeutics for complex diseases through advanced quantum computing and AI-driven drug discovery. Operating primarily in the pharmaceutical sector, the company specializes in precision medicine, targeting treatments for conditions such as cancer, neurological disorders, and rare diseases. QuantumPharm harnesses cutting-edge technology to streamline the drug development process, significantly reducing time to market and increasing the efficacy of its therapeutic solutions.

How the Company Makes Money

QuantumPharm generates revenue primarily through the commercialization of its pharmaceutical products, which include both proprietary drugs and those developed in collaboration with larger pharmaceutical companies. Key revenue streams include direct sales of approved drugs, licensing agreements for its proprietary technologies, and milestone payments from partnerships for co-development projects. Significant partnerships with major pharmaceutical firms enhance its research capabilities and provide access to broader distribution networks, contributing to its earnings. Additionally, the company may engage in government and private research grants that fund specific projects, further diversifying its revenue sources.

QuantumPharm, Inc. Financial Statement Overview

Summary

QuantumPharm, Inc. shows strong revenue growth but struggles with profitability, as evidenced by negative net profit margins and cash flows. Improvements in debt levels and equity position provide some stability, but the company must address operational inefficiencies to improve financial health.

Income Statement

QuantumPharm, Inc. has shown significant revenue growth from 2019 to 2024, yet the company struggles with profitability. Gross Profit Margin improved to 46.31% in 2024 from 27.66% in 2023, but the company continues to incur substantial net losses, with a Net Profit Margin of -569.33% in 2024. The negative EBIT and EBITDA margins highlight ongoing operational challenges.

Balance Sheet

The company has made notable improvements in its balance sheet, reducing total debt significantly from 2023 to 2024. The Debt-to-Equity Ratio has improved due to a positive equity position in 2024. However, the Equity Ratio remains a concern, reflecting potential financial instability.

Cash Flow

Operating Cash Flow has improved slightly, yet remains negative, impacting the company's ability to generate positive Free Cash Flow. Despite the improvement in financing activities, the Free Cash Flow to Net Income Ratio remains unfavorable, indicating ongoing cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2019
Income Statement
Total Revenue	680.88M	266.43M	174.42M	133.35M	62.80M	0.00
Gross Profit	511.39M	123.43M	48.24M	66.09M	32.78M	0.00
EBITDA	-243.20M	-631.38M	-1.78B	-495.00M	-2.11B	-9.84M
Net Income	-196.79M	-1.52B	-1.91B	-1.44B	-2.14B	-36.03M
Balance Sheet
Total Assets	7.72B	4.35B	4.01B	4.32B	4.38B	8.44M
Cash, Cash Equivalents and Short-Term Investments	5.32B	3.10B	2.83B	3.47B	3.83B	8.44M
Total Debt	366.10M	148.76M	11.04B	9.45B	7.83B	159.05M
Total Liabilities	689.47M	362.43M	11.25B	9.63B	7.99B	219.45M
Stockholders Equity	6.99B	3.96B	-7.27B	-5.33B	-3.61B	-211.01M
Cash Flow
Free Cash Flow	-475.64M	-536.79M	-698.20M	-627.83M	-417.42M	655.00K
Operating Cash Flow	-417.87M	-478.68M	-567.56M	-429.10M	-253.75M	655.00K
Investing Cash Flow	-1.69B	74.09M	735.58M	-2.76B	-70.47M	33.00K
Financing Cash Flow	3.13B	840.00M	-25.89M	57.99M	2.48B	0.00

QuantumPharm, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.57
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2228, the sentiment is Positive. The current price of 11.57 is below the 20-day moving average (MA) of 12.40, above the 50-day MA of 11.14, and above the 200-day MA of 7.07, indicating a neutral trend. The MACD of 0.06 indicates Positive momentum. The RSI at 49.48 is Neutral, neither overbought nor oversold. The STOCH value of 60.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2228.

QuantumPharm, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2268	―	HK$88.33B	59.12	19.62%	―	―	―
Sector *	―	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
2228	―	HK$48.17B	―	-3.55%	―	243.78%	97.15%
2502	―	HK$668.95M	―	-6.64%	5.49%	2.76%	-293.57%
2509	―	HK$6.61B	―	-64.62%	―	―	―
2498	―	HK$17.00B	-35.45	-10.42%	―	―	―
2511	―	HK$2.13B	―	-67.27%	―	―	47.42%

QuantumPharm, Inc. Corporate Events

XtalPi Holdings Clarifies Interim Results, Corrects Earnings Figures

XtalPi Holdings Limited, a company listed on the Hong Kong Stock Exchange, issued a clarification announcement regarding its interim results for the six months ended June 30, 2025. The company corrected errors in the reported number of ordinary shares and earnings per share figures, which were initially misstated in their interim results announcement. The corrected figures indicate a higher earnings per share than previously reported, which may positively impact stakeholders’ perception of the company’s financial performance.

The most recent analyst rating on (HK:2228) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Completes Successful Share Placement to Fund Technological Advancements

XtalPi Holdings Limited has successfully completed the placing of 285,920,000 new shares, representing approximately 6.64% of its enlarged issued share capital, at a price of HK$9.28 per share. The placing, which raised approximately HK$2,629.8 million in net proceeds, will primarily fund the company’s ongoing product iterations and upgrades, including advancements in its robotic laboratory technology and AI capabilities. These developments are expected to enhance XtalPi’s research and development technological capabilities, positioning the company to address key industry challenges and improve operational efficiency.

The most recent analyst rating on (HK:2228) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Holdings Announces New Share Placement to Raise HK$2.63 Billion

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, announced a significant financial move by entering into a Placing Agreement to issue new shares under a General Mandate. The company plans to issue up to 285,920,000 Placing Shares at a price of HK$9.28 per share, representing a discount to recent trading prices. This issuance could raise approximately HK$2,629.8 million in net proceeds, enhancing the company’s capital base. The completion of the Placing is contingent upon certain conditions being met, and investors are advised to exercise caution.

The most recent analyst rating on (HK:2228) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Reports Record Revenue Growth and Profitability in H1 2025

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, announced its interim financial results for the first half of 2025, reporting a significant revenue increase of 403.8% year-on-year to RMB517.1 million. The company achieved profitability for the first time on a half-year basis with an adjusted net profit of RMB141.6 million, marking a milestone in its growth trajectory. XtalPi’s business development was bolstered by a major collaboration with DoveTree Medicines LLC, contributing to a 615.2% surge in revenue from its drug discovery solutions business. The collaboration, which includes an initial payment of US$51 million and potential future payments, highlights the global recognition of XtalPi’s AI and robotics drug discovery platform.

The most recent analyst rating on (HK:2228) stock is a Hold with a HK$10.50 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Holdings Announces Upcoming Board Meeting for Interim Results

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced that its board of directors will hold a meeting on August 27, 2025. The meeting will focus on approving the interim results for the first half of 2025 and discussing the potential recommendation of a dividend payment.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi Holdings Announces Significant Financial Turnaround in H1 2025

XtalPi Holdings Limited, a company incorporated in the Cayman Islands, has announced a significant improvement in its financial performance for the first half of 2025. The company expects a substantial increase in revenue and a turnaround from a net loss to a net profit, primarily driven by its collaboration with DoveTree Medicines LLC using its AI drug discovery platform. This marks the first time the company has achieved half-year profits, indicating a positive shift in its operational and financial trajectory.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

XtalPi and DoveTree Enter Definitive Agreement for AI-Driven Drug Discovery

XtalPi Holdings Limited, through its subsidiary Shenzhen XtalPi Technology Co., Ltd., has entered into a definitive agreement with DoveTree Medicines LLC to leverage its AI drug discovery platform for developing small molecule and antibody drug candidates. This collaboration focuses on oncology, immunologic and inflammatory diseases, neurological disorders, and metabolic dysregulation, with DoveTree obtaining exclusive development and commercialization rights. The agreement includes an initial payment of $51 million to XtalPi, with potential further payments and royalties based on product sales.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.